Advertisement

ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis

      Highlights

      • The mechanisms of ErbB TKI-induced diarrhoea are likely different to chemotherapy.
      • This paper provides rationale for chloride secretion as a mechanistic hypothesis.
      • This paper reviews current management of ErbB TKI-induced diarrhoea.
      • This paper speculates on potential new therapies for ErbB TKI-induced diarrhoea.

      Abstract

      Diarrhoea is a common, debilitating and potentially life threatening toxicity of many cancer therapies. While the mechanisms of diarrhoea induced by traditional chemotherapy have been the focus of much research, the mechanism(s) of diarrhoea induced by small molecule ErbB TKI, have received relatively little attention. Given the increasing use of small molecule ErbB TKIs, identifying this mechanism is key to optimal cancer care. This paper critically reviews the literature and forms a hypothesis that diarrhoea induced by small molecule ErbB TKIs is driven by intestinal chloride secretion based on the negative regulation of chloride secretion by ErbB receptors being disrupted by tyrosine kinase inhibition.

      Keywords

      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lalla R.V.
        • et al.
        MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
        Cancer. 2014; 120: 1453-1461
        • Gibson R.J.
        • Stringer A.M.
        Chemotherapy-induced diarrhoea.
        Curr Opin Support Palliat Care. 2009; 3: 31-35
        • Benson 3rd, A.B.
        • et al.
        Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
        J Clin Oncol. 2004; 22: 2918-2926
        • Stein A.
        • Voigt W.
        • Jordan K.
        Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.
        Ther Adv Med Oncol. 2010; 2: 51-63
        • Foote M.
        The importance of planned dose of chemotherapy on time: do we need to change our clinical practice?.
        Oncologist. 1998; 3: 365-368
        • Di Fiore F.
        • Van Cutsem E.
        Acute and long-term gastrointestinal consequences of chemotherapy.
        Best Pract Res Clin Gastroenterol. 2009; 23: 113-124
        • Davila M.
        • Bresalier R.S.
        Gastrointestinal complications of oncologic therapy.
        Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 682-696
        • Vincenzi B.
        • et al.
        Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
        Nat Clin Pract Oncol. 2008; 5: 455-465
        • Carlotto A.
        • et al.
        The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.
        PharmacoEconomics. 2013; 31: 753-766
        • Elting L.S.
        • et al.
        The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis.
        Cancer. 2003; 98: 1531-1539
        • Lalla R.V.
        • et al.
        MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
        Cancer. 2014;
        • Hirsh V.
        • et al.
        Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.
        Curr Oncol. 2014; 21: 329-336
        • Belani C.P.
        The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
        Cancer Invest. 2010; 28: 413-423
        • Gibson R.J.
        • et al.
        Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
        J Gastroenterol Hepatol. 2003; 18: 1095-1100
        • Gibson R.J.
        • Keefe D.M.
        Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.
        Support Care Cancer. 2006; 14: 890-900
        • Sonis S.T.
        The pathobiology of mucositis.
        Nat Rev Cancer. 2004; 4: 277-284
        • Lin C.C.
        • et al.
        Profiles of circulating endothelial cells and serum cytokines during adjuvant chemoradiation in rectal cancer patients.
        Clin Transl Oncol. 2013; 15: 855-860
        • Sonis S.
        • et al.
        Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung.
        Support Care Cancer. 2014;
        • Logan R.M.
        • et al.
        The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs.
        Cancer Treat Rev. 2007; 33: 448-460
        • Logan R.M.
        • et al.
        Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
        Cancer Chemother Pharmacol. 2008; 62: 33-41
        • Keefe D.M.
        • et al.
        Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans.
        Gut. 2000; 47: 632-637
        • Keefe D.M.
        • Bateman E.H.
        Tumor control versus adverse events with targeted anticancer therapies.
        Nat Rev Clin Oncol. 2012; 9: 98-109
        • Takahashi T.
        • et al.
        Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
        Invest New Drugs. 2012; 30: 2352-2363
        • Pinkas-Kramarski R.
        • Alroy I.
        • Yarden Y.
        ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.
        J Mammary Gland Biol Neoplasia. 1997; 2: 97-107
        • Dent P.
        • et al.
        Stress and radiation-induced activation of multiple intracellular signaling pathways.
        Radiat Res. 2003; 159: 283-300
        • McCole D.F.
        • Barrett K.E.
        Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function.
        Acta Physiol. 2009; 195: 149-159
        • Henson E.S.
        • Gibson S.B.
        Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy.
        Cell Signal. 2006; 18: 2089-2097
        • Paul G.
        • et al.
        Interferon-gamma alters downstream signaling originating from epidermal growth factor receptor in intestinal epithelial cells: functional consequences for ion transport.
        J Biol Chem. 2012; 287: 2144-2155
        • Ayyappan S.
        • Prabhakar D.
        • Sharma N.
        Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
        Anticancer Res. 2013; 33: 4139-4155
        • Hare K.J.
        • et al.
        The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.
        Clin Cancer Res. 2007; 13: 5170-5175
        • Yarden Y.
        • Sliwkowski M.X.
        Untangling the ErbB signalling network.
        Nat Rev Mol Cell Biol. 2001; 2: 127-137
        • Chen C.L.
        • et al.
        Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis.
        Lab Invest. 2012; 92: 331-344
        • Dietrich E.
        • Antoniades K.
        Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology.
        Hippokratia. 2012; 16: 196-199
        • Masui H.
        • et al.
        Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
        Cancer Res. 1984; 44: 1002-1007
        • Normanno N.
        • et al.
        Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
        Endocr Relat Cancer. 2003; 10: 1-21
        • Sharma S.V.
        • et al.
        Epidermal growth factor receptor mutations in lung cancer.
        Nat Rev Cancer. 2007; 7: 169-181
        • Zandi R.
        • et al.
        Mechanisms for oncogenic activation of the epidermal growth factor receptor.
        Cell Signal. 2007; 19: 2013-2023
        • Mendelsohn J.
        Targeting the epidermal growth factor receptor for cancer therapy.
        J Clin Oncol. 2002; 20: 1S-13S
        • Liao B.C.
        • Lin C.C.
        • Yang J.C.
        Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
        Curr Opin Oncol. 2015; 27: 94-101
        • Herbst R.S.
        • et al.
        TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
        J Clin Oncol. 2005; 23: 5892-5899
        • Shepherd F.A.
        • et al.
        Erlotinib in previously treated non-small-cell lung cancer.
        N Engl J Med. 2005; 353: 123-132
        • Takeda M.
        • Okamoto I.
        • Nakagawa K.
        Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
        Lung Cancer. 2015; 88: 74-79
        • Loriot Y.
        • et al.
        Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
        Nat Clin Pract Oncol. 2008; 5: 268-278
        • Rasmussen A.R.
        • et al.
        The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.
        Dig Dis Sci. 2010; 55: 2785-2796
        • Yusta B.
        • et al.
        ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.
        Gastroenterology. 2009; 137: 986-996
        • Berlanga-Acosta J.
        • et al.
        Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats.
        Gut. 2001; 48: 803-807
        • Opleta-Madsen K.
        • Hardin J.
        • Gall D.G.
        Epidermal growth factor upregulates intestinal electrolyte and nutrient transport.
        Am J Physiol. 1991; 260: G807-G814
        • Goodlad R.A.
        • et al.
        Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity.
        Gut. 1991; 32: 994-998
        • Dignass A.U.
        • Podolsky D.K.
        Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta.
        Gastroenterology. 1993; 105: 1323-1332
        • Bowen J.M.
        Mechanisms of TKI-induced diarrhea in cancer patients.
        Curr Opin Support Palliat Care. 2013; 7: 162-167
        • Bowen J.M.
        • et al.
        Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
        Cancer Biol Ther. 2012; 13: 1269-1275
        • Bowen J.M.
        • et al.
        Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
        Cancer Chemother Pharmacol. 2014; 74: 617-627
        • Gibson R.J.
        • et al.
        Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
        Chemotherapy. 2007; 53: 360-369
        • Senderowicz A.M.
        • et al.
        Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
        J Clin Oncol. 1998; 16: 2986-2999
        • Senderowicz A.M.
        Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
        Invest New Drugs. 1999; 17: 313-320
        • Kahn M.E.
        • et al.
        Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
        Clin Cancer Res. 2001; 7: 343-349
        • Hoda M.R.
        • et al.
        Apical leptin induces chloride secretion by intestinal epithelial cells and in a rat model of acute chemotherapy-induced colitis.
        Am J Physiol Gastrointest Liver Physiol. 2010; 298: G714-G721
        • Huang F.S.
        • et al.
        Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury.
        Am J Physiol Gastrointest Liver Physiol. 2002; 282: G432-G442
        • Barrett K.E.
        • Keely S.J.
        Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects.
        Annu Rev Physiol. 2000; 62: 535-572
        • Dharmsathaphorn K.
        • Pandol S.J.
        Mechanism of chloride secretion induced by carbachol in a colonic epithelial cell line.
        J Clin Investig. 1986; 77: 348-354
        • Dharmsathaphorn K.
        • Cohn J.
        • Beuerlein G.
        Multiple calcium-mediated effector mechanisms regulate chloride secretory responses in T84-cells.
        Am J Physiol. 1989; 256: C1224-C1230
        • Uribe J.M.
        • et al.
        Epidermal growth factor inhibits Ca(2+)-dependent Cl-transport in T84 human colonic epithelial cells.
        Am J Physiol. 1996; 271: C914-C922
        • Keely S.J.
        • Barrett K.E.
        ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells.
        J Biol Chem. 1999; 274: 33449-33454
        • Chow J.Y.
        • Uribe J.M.
        • Barrett K.E.
        A role for protein kinase cepsilon in the inhibitory effect of epidermal growth factor on calcium-stimulated chloride secretion in human colonic epithelial cells.
        J Biol Chem. 2000; 275: 21169-21176
        • Deachapunya C.
        • Poonyachoti S.
        Activation of chloride secretion by isoflavone genistein in endometrial epithelial cells.
        Cell Physiol Biochem. 2013; 32: 1473-1486
        • Illek B.
        • Fischer H.
        • Machen T.E.
        Alternate stimulation of apical CFTR by genistein in epithelia.
        Am J Physiol. 1996; 270: C265-C275
        • Chen P.
        • et al.
        EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.
        Eur J Clin Pharmacol. 2011; 67: 235-243
        • Crown J.P.
        • et al.
        Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
        Breast Cancer Res Treat. 2008; 112: 317-325
        • Keefe D.M.
        • Gibson R.J.
        Mucosal injury from targeted anti-cancer therapy.
        Support Care Cancer. 2007; 15: 483-490
        • Medina P.J.
        • Goodin S.
        Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
        Clin Ther. 2008; 30: 1426-1447
        • Keisner S.V.
        • Shah S.R.
        Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
        Drugs. 2011; 71: 443-454
        • van Erp N.P.
        • Gelderblom H.
        • Guchelaar H.J.
        Clinical pharmacokinetics of tyrosine kinase inhibitors.
        Cancer Treat Rev. 2009; 35: 692-706
        • Cusatis G.
        • et al.
        Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
        J Natl Cancer Inst. 2006; 98: 1739-1742
        • Baker D.E.
        Loperamide: a pharmacological review.
        Rev Gastroenterol Disord. 2007; 7: S11-S18
        • Thiagarajah J.R.
        • et al.
        Discovery and development of antisecretory drugs for treating diarrheal diseases.
        Clin Gastroenterol Hepatol. 2014; 12: 204-209
        • Caci E.
        • et al.
        Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis.
        Biochem J. 2008; 413: 135-142
        • Ko E.A.
        • et al.
        Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice.
        Gut. 2014; 63: 1120-1129
        • Crutchley R.D.
        • Miller J.
        • Garey K.W.
        Crofelemer, a novel agent for treatment of secretory diarrhea.
        Ann Pharmacother. 2010; 44: 878-884
        • Cottreau J.
        • et al.
        Crofelemer for the treatment of secretory diarrhea.
        Expert Rev Gastroenterol Hepatol. 2012; 6: 17-23
        • Tradtrantip L.
        • Namkung W.
        • Verkman A.S.
        Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.
        Mol Pharmacol. 2010; 77: 69-78
        • Holodniy M.
        • et al.
        A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS.
        Am J Gastroenterol. 1999; 94: 3267-3273
        • DiCesare D.
        • et al.
        A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico.
        Am J Gastroenterol. 2002; 97: 2585-2588
        • Mangel A.W.
        • Chaturvedi P.
        Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
        Digestion. 2008; 78: 180-186
        • Keefe D.
        • Anthony L.
        Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.
        Curr Opin Support Palliat Care. 2008; 2: 19-21